+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis

Infliximab in refractory pouchitis complicated by fistulae following ileo-anal pouch for ulcerative colitis

Alimentary Pharmacology & Therapeutics 17(10): 1263-1271

Aim: To determine the efficacy of infliximab in the treatment of chronic refractory pouchitis complicated by fistulae following ileal pouch-anal anastomosis for ulcerative colitis. Methods: This open study included seven patients (four females, three males) with chronic refractory pouchitis complicated by fistulae. Pouchitis was diagnosed by clinical, endoscopic and histological criteria. The sites of the fistulae were as follows: pouch-bladder in one, vaginal in three, perianal in two, and both vaginal and perianal in one. Extra-intestinal manifestations (erythema nodosum, arthralgia) were present in four patients. Crohn's disease was carefully excluded in all patients after re-evaluation of the history, re-examination of the original proctocolectomy specimen and examination of the proximal small bowel. All patients had been treated with antibiotics and three with steroids. Patients received infliximab, 5 mg/kg, at 0, 2 and 6 weeks. Azathioprine (2.5 mg/kg) was also started for all patients as bridge therapy. Clinical response was classified as complete, partial or no response. Fistulae closure was classified as complete (cessation of fistulae drainage and total closure of all fistulae), partial (a reduction in the number, size, drainage or discomfort associated with fistulae) or no closure. The pouchitis disease activity index and quality of life were also used as outcome measures. Results: Clinically, all patients improved. At the 10-week follow-up, six of the seven patients had a complete clinical response, and five had complete fistulae closure. At the 10-week follow-up, the median pouchitis disease activity index decreased from 12 (baseline) (range, 10-15) to 5 (range, 3-8); the median quality of life decreased from 37 points (range, 33-40) to 14 (range, 9-18). Erythema nodosum and arthralgia showed complete remission soon after the first infusion of infliximab. Conclusions: These preliminary results indicate that infliximab may be recommended for the treatment of refractory pouchitis complicated by fistulae following ileal pouch-anal anastomosis for ulcerative colitis.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 010836079

Download citation: RISBibTeXText

PMID: 12755839

DOI: 10.1046/j.1365-2036.2003.01535.x

Related references

Are ASCA ulcerative colitis patients at higher risk for refractory pouchitis and pouch fistulae?. Gastroenterology 118(4 Suppl 2 Part 1): A106, 2000

Systematic Review With Meta-Analysis: Anti-TNF Therapy in Refractory Pouchitis and Crohn's Disease-Like Complications of the Pouch After Ileal Pouch-Anal Anastomosis Following Colectomy for Ulcerative Colitis. Inflammatory Bowel Diseases 24(2): 261-268, 2018

An uncommon complication of chronic antibiotics refractory pouchitis after ileal pouch-anal anastomosis for ulcerative colitis. Gastroenterology 147(4): 743-744, 2014

Frequency, Clinical Features and Factors Associated with Pouchitis after Proctocolectomy with Ileo-Pouch-Anal Anastomosis in Patients with Ulcerative Colitis: A Latin-American Country Retrospective-Cohort Study. Digestive Surgery 32(6): 489-495, 2016

Value of histopathology for predicting the post-operative complications of ileo-anal anastomosis (J-pouch) procedure in children with refractory ulcerative colitis. Pathology 48(4): 330-335, 2016

Early first episode of pouchitis after ileal pouch-anal anastomosis for pediatric ulcerative colitis is a risk factor for development of chronic pouchitis. Journal of Pediatric Surgery 54(9): 1788-1793, 2019

Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflammatory Bowel Diseases 25(9): 1569-1576, 2019

Risk factors for pouchitis after ileal pouch-anal anastomosis for ulcerative colitis or indeterminate colitis: A population-based study. 2007

Pouchitis in Pediatric Ulcerative Colitis Patients After Ileal Pouch Anal Anastomosis. Journal of Pediatric Gastroenterology and Nutrition 63(6): E211, 2016

Pitfalls and outcome in ileo-anal pouch surgery for ulcerative colitis. Netherlands Journal Of Medicine. 50(2): S23-S27, 1997

Problems after ileo-pouch anal anastomosis for ulcerative colitis. How can we prevent it? What can we do?. Netherlands Journal of Medicine 45(2): 80-85, 1994

Predictors for Pouchitis After Ileal Pouch-Anal Anastomosis for Pediatric-Onset Ulcerative Colitis. Journal of Surgical Research 238: 72-78, 2019

Sulfasalazine in Prevention of Pouchitis After Proctocolectomy with Ileal Pouch-Anal Anastomosis for Ulcerative Colitis. Digestive Diseases and Sciences 62(4): 1016-1024, 2017

Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database of Systematic Reviews 2015(11): Cd001176, 2015

Predictors of pouchitis after ileal pouch-anal anastomosis in pediatric-onset ulcerative colitis. European Journal of Gastroenterology and Hepatology 29(9): 1079-1085, 2017